Acoustic sensitizer for sonodynamic therapy, preparation method of acoustic sensitizer and application of acoustic sensitizer in tumor resistance
By preparing L-polylysine-methylene blue nanoparticles as a sonosensitive agent, the problem of methylene blue's easy inactivation in vivo was solved, achieving highly efficient anti-cancer effects and rapid drug release at the tumor site in sonodynamic therapy, thus enhancing the anti-cancer effect and reducing side effects.
Patent Information
- Application Number
- CN202410948505.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-16
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-07-16
AI Technical Summary
Existing methylene blue is easily reduced in vivo and loses its photodynamic activity, which affects the anti-tumor effect of sonodynamic therapy.
L-polylysine-methylene blue nanoparticles were prepared by self-assembly to form a sonic sensitizer. The methylene blue was then activated by ultrasound to generate reactive oxygen species, thereby achieving selective protection and rapid release at the tumor site.
It improves the anti-cancer effect of sonodynamic therapy, reduces damage to normal tissues, achieves specific and rapid drug release at the tumor site, enhances the anti-cancer effect and reduces side effects.
Smart Images

Figure CN118894993A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a sonosensitizer for sonodynamic therapy and a preparation method thereof and application in anti-tumor, belonging to the technical field of medicine. Background Art
[0002] Sonodynamic therapy (SDT) is a method that uses ultrasound to penetrate deep into tissues and activate the anti-tumor effects of some sonosensitizer drugs (such as hematoporphyrin, methylene blue, etc.). It is a new anti-tumor treatment method following chemotherapy, radiotherapy, photodynamic therapy and immunotherapy. However, conventional sonosensitizers have certain problems, such as short half-life, phototoxicity and damage to normal tissues. The above problems will inevitably affect the industrialization of new sonosensitizers and the clinical application of SDT.
[0003] Methylene blue (MB) is a water-soluble photosensitizer and sonosensitizer that has been widely used in photodynamic therapy (PDT). It has a high singlet oxygen ( 1 O2) yield, and has become a photosensitizer with great application value. However, under in vitro conditions, pure MB will decompose under visible light irradiation; in vivo, it is also easily reduced to white methylene blue (LMB) by myocardial diaphorase, losing its photodynamic activity. Therefore, it is urgent to develop a method that can protect MB, activate it after reaching cancer tissue, and exert SDT or PDT effect for anti-cancer. Summary of the invention
[0004] In order to solve the problem that the existing methylene blue is easily inactivated, the present invention provides a sonosensitizer for sonodynamic therapy, a preparation method thereof and an application thereof in anti-tumor.
[0005] The technical solution of the present invention:
[0006] One of the purposes of the present invention is to provide a sonosensitizer, which is a nanoparticle self-assembled from L-polylysine-methylene blue. The structural formula of the L-polylysine-methylene blue is as follows:
[0007]
[0008] Wherein n is an integer.
[0009] The second object of the present invention is to provide a method for preparing the above-mentioned sonosensitizer, which method comprises the following steps:
[0010] (1) Synthesis of L-lysine-methylene blue-N-carboxyl ring anhydride;
[0011] (2) using aminopolyethylene glycol monomethyl ether 5K to initiate the ring-opening polymerization of L-lysine-methylene blue-N-carboxyl ring inner acid anhydride to obtain L-polylysine-methylene blue;
[0012] (3) L-polylysine-methylene blue is self-assembled into nanoparticles, and the obtained nanoparticles are sonosensitizers.
[0013] Further defined, the operation process of (1) is:
[0014] Heat anhydrous tetrahydrofuran under oil bath conditions, and add Lys-MB and triphosgene under the condition of passing nitrogen, stir the reaction until the solution is clear and transparent, continue stirring for 4 hours, stop heating and increase the nitrogen flux. After 15 minutes, precipitate the mixed solution in frozen n-hexane and store at -20°C for 2 hours. Filter, dissolve the crude product in frozen ethyl acetate, and then wash with saturated sodium bicarbonate solution. Dry the organic phase with anhydrous magnesium sulfate, use a G4 sand core filter to filter out the magnesium sulfate and transfer it to an ammonia bottle, connect a cold trap oil pump to dry, and finally use anhydrous tetrahydrofuran / n-hexane as raw material, filter, rotary evaporation, and recrystallization to obtain L-lysine-methylene blue-N-carboxyl ring anhydride.
[0015] It is further defined that the ratio of anhydrous tetrahydrofuran, Lys-MB and triphosgene is 200 mL: 6.56 mmol: 39.33 mmol.
[0016] It is further defined that the oil bath temperature is 45°C.
[0017] It is further defined that the synthesis process of Lys-MB is as follows: Boc-Lys-OH, NaOH, THF and water are mixed, and the mixture is dropped into a solution containing MBCl and THF under ice bath conditions. After reacting for 12 hours, THF is removed by rotary evaporation, the pH is adjusted to 1 with hydrochloric acid, and DCM is extracted multiple times, and then DCM is removed by rotary evaporation. A mixed solvent of TFA and DCM is added, and after reacting for 6 hours, it is precipitated in a mixed solvent of ether and petroleum ether, and the precipitate is drained to obtain a dark blue solid, which is Lys-MB.
[0018] It is further defined that the ratio of Boc-Lys-OH, NaOH, THF and water is 40.19 mmol:40.00 mmol:60 mL:30 mL.
[0019] It is further defined that the solution containing MBCl and THF contains 20.12 mmol of MBCl and 90 mL of THF.
[0020] Further defined, THF was removed by rotary evaporation at 40°C.
[0021] Furthermore, the number of DCM extractions is limited to 10.
[0022] Further defined, DCM was removed by rotary evaporation at 33°C.
[0023] Furthermore, the mixed solvent of TFA and DCM is prepared in a volume ratio of 1:1.
[0024] It is further defined that a mixed solvent of ether and petroleum ether is prepared in a volume ratio of 1:1.
[0025] Further, the synthesis process of MBCl is as follows: methylene blue is dissolved in water, dichloromethane and dichloromethane are added, the reaction is heated and stirred under a nitrogen atmosphere, sodium dithionite solution is added, the reaction is continued until the solution turns yellow, and then cooled in an ice-water bath, and then dichloromethane containing triphosgene is added, and the reaction is stirred for 1.5 hours, and then the reaction solution is poured into ice water under stirring conditions, and then the resulting mixture is extracted with dichloromethane, and finally washed with a saturated NaCl solution, dried over anhydrous magnesium sulfate, evaporated on a rotary evaporator, and column chromatography is performed to obtain white solid MBCl.
[0026] It is further defined that the ratio of methylene blue, water, dichloromethane and dichloromethane is 31.26mmol:100mL:50mL:125.01mmol.
[0027] It is further defined that the sodium dithionite solution contains 125.09 mmol of sodium dithionite and 150 mL of water.
[0028] It is further defined that the triphosgene in the dichloromethane containing triphosgene is 18.77 mmol and the dichloromethane is 50 mL.
[0029] It is further defined that the column chromatography solvent is a mixture of petroleum ether and dichloromethane in a volume ratio of 2:3.
[0030] Further defined, the operation process of (2) is: under a nitrogen atmosphere, L-lysine-methylene blue-N-carboxyl ring anhydride, DMF and aminopolyethylene glycol monomethyl ether 5K are mixed, and reacted at room temperature in the dark for 48 hours, and the reaction solution is transferred to a dialysis bag with a molecular weight cutoff of 3500, dialyzed with water and then freeze-dried to obtain L-polylysine-methylene blue.
[0031] Furthermore, the ratio of L-lysine-methylene blue-N-carboxyl ring anhydride, DMF and amino polyethylene glycol monomethyl ether 5K is 2.00 mmol:15 mL:0.02 mmol.
[0032] Further defined, the operation process of (3) is as follows: weigh 10 mg of L-polylysine-methylene blue, dissolve it in 2 mL of DMF, add it dropwise into 20 mL of deionized water while stirring, stir for 2-4 h to allow it to self-assemble into nanoparticles, then dialyze with deionized water for 24 h to remove DMF in the solution, and make the volume to 25 mL to obtain the sonosensitizer.
[0033] The third object of the present invention is to provide an application of the above-mentioned sonosensitizer in sonodynamic therapy.
[0034] A fourth object of the present invention is to provide an application of the above-mentioned sonosensitizer in the preparation of medicines.
[0035] A fifth object of the present invention is to provide an anti-tumor pharmaceutical composition, which comprises the above-mentioned sonosensitizer and an anticancer drug and / or an immune agonist loaded on the sonosensitizer.
[0036] It is further defined that the immune agonist is resiquimod R848.
[0037] Beneficial effects:
[0038] The present invention synthesizes a small molecule of N-carboxyl ring anhydride containing methylene blue, and further utilizes the ring-opening polymerization thereof to obtain an amphiphilic block copolymer PEG-PMB, the block copolymer PEG-PMB has good biocompatibility and biodegradability, and the nanoparticles PMB-NPs assembled in water generate reactive oxygen species (ROS) through the SDT action, which can kill cancer cells, that is, the present invention synthesizes an environmentally friendly SDT preparation. Further, the urea bond connected to the methylene blue in the PEG-PMB molecule synthesized by the present invention is an ultrasound-responsive group, and only under the action of ultrasound (US) will MB be released, so MB has a selective protective effect. In addition, the content of MB per unit mass of the obtained nanoparticle PMB-NPs is high, which improves the anti-cancer effect mediated by SDT. And the sonosensitizer can be combined with an anticancer drug and / or an immune agonist to achieve the specific and rapid release of the drug at the tumor site, achieving the anti-cancer goal of enhancing efficacy and reducing toxicity. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 The Lys-MB-NCA prepared in Example 1 1 H NMR spectrum;
[0040] Figure 2 This is the ESI-MS spectrum of Lys-MB-NCA prepared in Example 1;
[0041] Figure 3 FITR spectra of Lys-MB and Lys-MB-NCA prepared in Example 1;
[0042] Figure 4 The PEG-PMB prepared in Example 1 1 H NMR spectrum;
[0043] Figure 5 This is a comparison chart of the GPC test results of PEG-PMB and mPEG5K-NH2 prepared in Example 1;
[0044] Figure 6 The figure is the dynamic light scattering (DLS) test result of PMB-NPs prepared in Example 1 before and after ultrasound;
[0045] Figure 7 TEM image of PMB-NPs prepared in Example 1 before ultrasound;
[0046] Figure 8 TEM image of PMB-NPs prepared in Example 1 after ultrasound treatment;
[0047] Fig. 9 The comparison diagram of the ultraviolet absorption spectra of PMB-NPs prepared in Example 1 at 0min, 10min, 20min, 30min, 40min and 50min of ultrasound;
[0048] Fig.10 The PMB-NPs prepared in Example 1 were tested after ultrasound at 0 min, 10 min, 20 min, 30 min, 40 min and 50 min. 1 The fluorescence spectrum of O2 generation;
[0049] Fig.11 This is a comparison of the MTT of 4T1 cells treated with PMB-NPs prepared in Example 1 for 24 h under ultrasonic and non-ultrasonic conditions;
[0050] Fig.12 The dynamic light scattering (DLS) test results of PMB@R848-NPs prepared in Example 1 before and after ultrasound;
[0051] Fig.13 TEM image of PMB@R848-NPs prepared in Example 1 before ultrasound;
[0052] Fig.14 TEM image of PMB@R848-NPs prepared in Example 1 after ultrasound treatment;
[0053] Fig.15 The fluorescence spectra of PMB@R848-NPs prepared in Example 1 releasing R848 in response to ultrasound under physiological conditions (pH 7.4) and in the tumor microenvironment (pH 5.0);
[0054] Fig.16 This is the MTT test result of PMB@R848-NPs prepared in Example 1 on mouse breast cancer cells (4T1) before and after ultrasound. DETAILED DESCRIPTION
[0055] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with the embodiments of the specification.
[0056] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein, and those skilled in the art may make similar generalizations without violating the connotation of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.
[0057] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The term "in one embodiment" that appears in different places in this specification does not necessarily refer to the same embodiment, nor does it refer to a separate or selective embodiment that is mutually exclusive with other embodiments.
[0058] The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, methods and instruments used are conventional materials, reagents, methods and instruments in the art unless otherwise specified, and can be obtained through commercial channels by those skilled in the art, and the purity of the solid and liquid reagents used is analytically pure.
[0059] Example 1
[0060] Step 1: Synthesis of Methylene Blue Chloride (MBCl)
[0061] Dissolve methylene blue (10.00 g, 31.26 mmol, 1.0 eq) in 100 mL of water, add dichloromethane (50 mL) and Na2CO3 (13.25 g, 125.01 mmol, 4.0 eq), and stir at 40 °C under nitrogen atmosphere. Dissolve sodium dithionite (21.78 g, 125.09 mmol, 4.0 eq) in 150 mL of water and add directly to the solution with a syringe. Stir the mixture at 40 °C under nitrogen atmosphere. After the solution turns yellow, cool it with an ice-water bath, drop triphosgene (5.57 g, 18.77 mmol, 0.6 eq) into 50 mL of dichloromethane, and stir for another 1.5 h. Then pour the solution into 300 mL of ice water while stirring, and extract the resulting mixture with 5×100 mL portions of dichloromethane. Finally, the product was washed with saturated NaCl solution, dried over anhydrous magnesium sulfate, evaporated by rotary evaporator, and purified by column chromatography (petroleum ether / dichloromethane 2 / 3, vol) to obtain white solid MBCl with a yield of 7.00 g and a yield of 64.52%.
[0062] Step 2: Synthesis of L-lysine-methylene blue (Lys-MB)
[0063] Boc-Lys-OH (9.90 g, 40.19 mmol, 2.0 eq) and NaOH (1.60 g, 40.00 mmol, 2.0 eq) were dissolved in 60 mL THF and 30 mL water. The mixed solution was dropped into a round-bottom flask containing MBCl (7.00 g, 20.12 mmol, 1.0 eq) and 90 mL THF in an ice bath and reacted for 12 h. THF was removed by rotary evaporation at 40 °C, and the pH was adjusted to 1 with hydrochloric acid. It was extracted 10 times with 30 mL DCM. DCM was removed by rotary evaporation at 33 °C, and 80 mL of mixed solvent (TFA / DCM=1 / 1, vol) was added to the flask, and the reaction was continued for 6 h, and then settled in 800 mL of mixed solvent (ether / petroleum ether=1 / 1, vol), and the precipitate was drained to obtain Lys-MB as a dark blue solid with a yield of 7.20 g and a yield of 78.18%).
[0064] Step 3: Synthesis of L-lysine-methylene blue-N-carboxyl ring anhydride (Lys-MB-NCA)
[0065] Bake the three-necked flask three times, add 200mL of anhydrous tetrahydrofuran, and pass N2 through a glass tube at about 2-3 bubbles per second. Place the flask in an oil bath and heat it to 45°C. Add Lys-MB (3.00g, 6.56mmol, 1.0eq), and then add triphosgene (11.68g, 39.33mmol, 6.0eq). Stir the reaction until the solution becomes clear and transparent, and continue stirring for 4h. Stop heating, withdraw the oil bath, unplug, and increase the amount of nitrogen to blow for 15min. Then precipitate the mixed solution in 1L of frozen n-hexane and store at -20°C for 2h. Finally, filter to obtain the crude product, redissolve it in 200mL of frozen ethyl acetate, and wash it three times with saturated sodium bicarbonate solution. Dry the organic phase with anhydrous magnesium sulfate overnight, then filter out the magnesium sulfate with a G4 sand core funnel, transfer it to the baked ammonia bottle, and connect the cold trap oil pump to dry it. Using anhydrous tetrahydrofuran / n-hexane as raw materials, L-lysine-methylene blue-N-carboxyl ring anhydride (Lys-MB-NCA) was obtained by filtration, rotary evaporation and recrystallization. The yield was 1.12 g and the yield rate was 35.33%.
[0066] The obtained product Lys-MB-NCA was characterized by nuclear magnetic resonance hydrogen spectrum (300M), and the results were as follows Figure 1 As shown by Figure 1 It can be seen that the chemical shift and integration can prove that this method successfully synthesizes L-lysine-methylene blue-N-carboxyl ring anhydride with the following structural formula:
[0067]
[0068] The product Lys-MB-NCA was further analyzed by ESI mass spectrometry. Figure 2 As shown by Figure 2 It can be seen that the theoretical mass-to-charge ratio (m / z) is 483.19, and the actual test values are 484.19 and 506.18, which further proves the successful synthesis of L-lysine-methylene blue-N-carboxyl ring anhydride (Lys-MB-NCA).
[0069] The products Lys-MB-NCA and Lys-MB were further characterized by infrared spectroscopy. Figure 3 As shown by Figure 3 It can be seen that after the reaction, the 1120 cm -1 The characteristic peaks of α carbon and amino group disappeared after the reaction and were replaced by 1850cm -1 and 1780 cm -1 The stretching vibration peaks of the two carbonyl groups in the anhydride further verified the successful synthesis of L-lysine-methylene blue-N-carboxyl anhydride (Lys-MB-NCA).
[0070] Step 4: Synthesis of L-polylysine-methylene blue (PEG-PMB)
[0071] The synthetic route is as follows:
[0072]
[0073] The specific synthesis process is as follows: take a round-bottom flask and bake it 3 times, replace nitrogen 3 times, add L-lysine-methylene blue-N-carboxyl ring anhydride (0.96g, 2.00mmol, 100eq) and anhydrous DMF 15mL under nitrogen environment, then add mPEG5K-NH2 (0.10g, 0.02mmol, 1.0eq), and react at room temperature in the dark for 48h. The obtained reaction solution is transferred to a dialysis bag with a molecular weight cutoff of 3500, and dialyzed with water for 72h, changing the water every 2h, and finally freeze-dried to obtain L-polylysine-methylene blue (PEG-PMB), with a yield of 0.81g and a yield of 82.57%.
[0074] The obtained product PEG-PMB was characterized by hydrogen nuclear magnetic resonance spectroscopy (300M). Figure 4 As shown by Figure 4 It can be seen that both the chemical shift and the integral can prove that this method successfully synthesized L-polylysine-methylene blue (PEG-PMB).
[0075] The product PEG-PMB and mPEG5K-NH2 were further subjected to gel permeation chromatography (GPC) of DMF mobile phase as shown in FIG. Figure 5 As shown by Figure 5It can be seen that the number average molecular weight of mPEG5K-NH2 is (11900, PDI=1.05), and the number average molecular weight of PEG-PMB is (31500, PDI=1.22). The successful polymerization of L-polylysine-methylene blue is proved by the peak time, molecular weight and distribution.
[0076] Step 4: Synthesis of poly-L-lysine-methylene blue nanoparticles (PMB-NPs)
[0077] L-polylysine-methylene blue nanoparticles (PMB-NPs) were prepared by conventional dialysis method. The specific operation process was as follows: 10 mg PEG-PMB was weighed, dissolved in 2 mL DMF, and added dropwise to 20 mL deionized water while stirring. The mixture was stirred for 3 h to allow it to self-assemble into nanoparticles. The DMF in the solution was then removed by dialysis with deionized water for 24 h, and the volume was fixed to 25 mL to obtain PMB-NPs.
[0078] The obtained product PMB-NPs before and after ultrasound (ultrasound conditions: 1MHz, 1.0W / cm 2 The dynamic light scattering (DLS) test results of 50% duty cycle and continuous ultrasound for 5 min are as follows: Figure 6 As shown by Figure 6 It can be seen that the water phase diameter of PMB-NPs is (143.6nm), and the water phase diameter becomes (188.4nm) after ultrasound. It may be that ultrasound makes PMB-NPs looser, which proves the successful assembly of L-polylysine-methylene blue nanoparticles (PMB-NPs).
[0079] Further, L-polylysine-methylene blue nanoparticles (PMB-NPs) were subjected to ultrasound before and after ultrasound (ultrasound conditions: 1 MHz, 1.0 W / cm 2 , 50% duty cycle, continuous ultrasound for 5 min) as shown in the transmission electron microscope (TEM) image. Figure 7 and 8 As shown by Figure 7 It can be seen that PMB-NPs are more compact and more uniform in size. Figure 8 It can be seen that the PMB-NPs are more dispersed after ultrasound, and the L-poly-lysine-methylene blue nanoparticles (PMB-NPs) are spherical before and after ultrasound, which further proves the successful assembly of PMB-NPs.
[0080] Further, L-polylysine-methylene blue nanoparticles (PMB-NPs) were subjected to ultrasound for 0 min, 10 min, 20 min, 30 min, 40 min and 50 min (ultrasound conditions: 1 MHz, 1.0 W / cm 2 , 50% duty cycle) is shown in the UV absorption spectrum Fig. 9 As shown by Fig. 9 It can be seen that with the extension of ultrasound time, the absorption peak of MB at 664nm gradually increased and reached the maximum value at 50min of ultrasound, which proved that L-polylysine-methylene blue nanoparticles (PMB-NPs) can effectively release MB after ultrasound.
[0081] Further, L-poly-lysine-methylene blue nanoparticles (PMB-NPs) were subjected to ultrasound for 0 min, 10 min, 20 min, 30 min, 40 min and 50 min (ultrasound conditions: 1 MHz, 1.0 W / cm 2 , 50% duty cycle), detected by 9,10-anthracenediyl-bis(methylene)dicarboxylic acid (ABDA) 1 The fluorescence spectrum of O2 is as follows: Fig.10 As shown by Fig.10 It can be seen that with the extension of ultrasound time, the peak of ABDA gradually decreases. This is because MB is separated from PMB-NPs after ultrasound. 1 O2, ABDA 1 O2 oxidation caused the peak to decrease, proving that ultrasound of PMB-NPs can release MB and produce 1 O2.
[0082] L-polylysine-methylene blue nanoparticles (PMB-NPs) before and after ultrasound (ultrasound conditions: 1 MHz, 1.0 W / cm 2 , 50% duty cycle, continuous ultrasound for 5 min) on mouse breast cancer cells (4T1) by MTT assay. The results are as follows Fig.11 As shown by Fig.11 It can be seen that the PMB-NPs group had no inhibitory effect on 4T1 cells under the same dose of MB, while the PMB-NPs+US group showed a significant inhibitory effect. This is because PMB-NPs produced a large amount of 1 O2, 1 O2, as a type of ROS, can damage DNA in the cell nucleus and cause apoptosis of tumor cells. This proves that the synthesized L-polylysine-methylene blue nanoparticles (PMB-NPs) have ultrasound response.
[0083] Step 5: Synthesis of anti-tumor drug composition (PMB@R848-NPs)
[0084] Using L-polylysine-methylene blue nanoparticles (PMB-NPs) as the carrier, R848 was physically loaded on PMB-NPs by conventional dialysis method. The specific operation process was as follows: 19.48 mg PMB-NPs and 4.9 mg R848 (the drug loading amount was designed to be 20%) were weighed, dissolved in 4 mL DMF, and added dropwise to 30 mL deionized water while stirring. After stirring for 3 hours, it was self-assembled into nanoparticles. Then, the solution was dialyzed with deionized water for 24 hours to remove DMF, and the volume was fixed to 50 mL, which was PMB@R848-NPs.
[0085] The product PMB@R848-NPs was obtained before and after ultrasound (ultrasound conditions: 1MHz, 1.0W / cm 2 The dynamic light scattering (DLS) test results of 50% duty cycle and continuous ultrasound for 5 min are as follows: Fig.12 As shown by Fig.12 It can be seen that the water phase diameter of PMB@R848-NPs is (93.4nm), which is smaller than that of PMB-NPs. This is due to the effect of shear force. After the PEG-PMB shell wraps the hydrophobic R848, the entire nanoparticles become more compact; after ultrasound, the water phase diameter becomes (172.1nm), which may be caused by ultrasound. The NPs are looser. The above proves that the assembly of L-polylysine-methylene blue-loaded R848 nanoparticles is successful.
[0086] Further PMB@R848-NPs before and after ultrasound (ultrasound conditions: 1 MHz, 1.0 W / cm 2 , 50% duty cycle, continuous ultrasound for 5 min) as shown in the transmission electron microscope (TEM) image. Fig.13 and 14 As shown, compared Fig.13 and Fig.14 It can be seen that PMB@R848-NPs are more compact and uniform in size before ultrasound. After ultrasound, PMB@R848-NPs+US are more dispersed, and PMB@R848-NPs are spherical before and after ultrasound, further proving that L-polylysine-methylene blue-loaded R848 nanoparticles are successfully assembled.
[0087] Further, the fluorescence spectra of PMB@R848-NPs releasing R848 in response to ultrasound at pH 7.4 under physiological conditions and pH 5.0 under tumor microenvironment are shown in Figure 2. Fig.15 As shown by Fig.15 It can be seen that PMB@R848-NPs release more R848 under acidic conditions, which is caused by protonation; at the same time, the ultrasonic conditions after ultrasound are: 1MHz, 1.0W / cm 2, 50% duty cycle, continuous ultrasound for 5 min) PMB@R848-NPs are more dispersed, which can increase the release of R848, reflecting the specificity of ultrasound therapy of PMB@R848-NPs in the tumor environment.
[0088] Further PMB@R848-NPs before and after ultrasound (ultrasound conditions: 1 MHz, 1.0 W / cm 2 , 50% duty cycle, continuous ultrasound for 5 min) on mouse breast cancer cells (4T1) by MTT assay. The results are as follows Fig.16 As shown by Fig.16 It can be seen that the PMB@R848-NPs group had no inhibitory effect on 4T1 cells under the same dose of MB, while the PMB@R848-NPs+US group showed a significant inhibitory effect, which was because PMB NPs produced a large amount of 1 O2 can damage DNA in the cell nucleus and cause apoptosis of tumor cells, which proves that we have successfully synthesized a new type of ultrasound-responsive L-polylysine-methylene blue-loaded R848 nanoparticles. It can reduce the use of large doses of R848, avoid side effects, and achieve specific and rapid release at the tumor site, achieving the anti-cancer goal of increasing efficacy and reducing toxicity.
[0089] Comparative Example 1
[0090] The difference between this comparative example and Example 1 is step 3, and the operations of the remaining steps 1, 2 and 4 are the same as those of Example 1. Specifically, step 3 of this comparative example is:
[0091] Lys-MB (0.042 g, 0.92 mmol, 1.0 eq), triphosgene (0.82 g, 2.76 mmol, 6.0 eq) and 100 mL of anhydrous THF were added to a round-bottom flask filled with N2 and stirred at 40 °C for 3 h. The mixture was precipitated in 1 L of frozen petroleum ether and stored at -20 °C for 2 h. The crude product was filtered and redissolved in 100 mL of frozen ethyl acetate. Washed three times with ice water and then twice with saturated sodium bicarbonate solution. The organic solvent was collected and dried over anhydrous magnesium sulfate overnight. After filtration, rotary evaporation and recrystallization, Lys-MB-NCA was obtained as a dark blue oily product with a yield of 85 mg and a yield of 19.32%.
[0092] Although the present invention has been disclosed as above in the preferred embodiments, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.
Claims
1. A sonosensitizer, characterized in that: The sonosensitizer is a nanoparticle formed by self-assembly of L-polylysine-methylene blue, and the structural formula of the L-polylysine-methylene blue is as follows: Wherein n is an integer.
2. A method for preparing the sonosensitizer according to claim 1, characterized in that: include: (1) Synthesis of L-lysine-methylene blue-N-carboxyl ring anhydride; (2) using aminopolyethylene glycol monomethyl ether 5K to initiate the ring-opening polymerization of L-lysine-methylene blue-N-carboxyl ring inner acid anhydride to obtain L-polylysine-methylene blue; (3) L-polylysine-methylene blue is self-assembled into nanoparticles, and the obtained nanoparticles are sonosensitizers.
3. The method for preparing the sonosensitizer according to claim 2, characterized in that: The operation process of (1) is as follows: Heat anhydrous tetrahydrofuran under oil bath conditions, and add Lys-MB and triphosgene under the condition of passing nitrogen, stir the reaction until the solution is clear and transparent, continue stirring for 4 hours, stop heating and increase the nitrogen flux. After 15 minutes, precipitate the mixed solution in frozen n-hexane and store at -20°C for 2 hours. Filter, dissolve the crude product in frozen ethyl acetate, and then wash with saturated sodium bicarbonate solution. Dry the organic phase with anhydrous magnesium sulfate, use a G4 sand core filter to filter out the magnesium sulfate and transfer it to an ammonia bottle, connect a cold trap oil pump to dry, and finally use anhydrous tetrahydrofuran / n-hexane as raw material, filter, rotary evaporation, and recrystallization to obtain L-lysine-methylene blue-N-carboxyl ring anhydride.
4. The method for preparing the sonosensitizer according to claim 3, characterized in that: The synthesis process of Lys-MB is as follows: Boc-Lys-OH, NaOH, THF and water are mixed, and the mixture is dropped into a solution containing MBCl and THF under ice bath conditions. After reacting for 12 hours, THF is removed by rotary evaporation, the pH is adjusted to 1 with hydrochloric acid, and DCM is extracted multiple times, and then DCM is removed by rotary evaporation. A mixed solvent of TFA and DCM is added, and after reacting for 6 hours, it is precipitated in a mixed solvent of ether and petroleum ether. The precipitate is drained to obtain a dark blue solid, which is Lys-MB.
5. The method for preparing the sonosensitizer according to claim 4, characterized in that: The synthesis process of MBCl is as follows: methylene blue is dissolved in water, dichloromethane and dichloromethane are added, the mixture is heated and stirred under a nitrogen atmosphere, a sodium dithionite solution is added, the reaction is continued until the solution turns yellow, the mixture is cooled in an ice-water bath, and then dichloromethane containing triphosgene is added. After stirring for 1.5 hours, the reaction solution is poured into ice water under stirring, and the mixture is extracted with dichloromethane. Finally, the mixture is washed with a saturated NaCl solution, dried over anhydrous magnesium sulfate, evaporated on a rotary evaporator, and subjected to column chromatography to obtain white solid MBCl.
6. The method for preparing the sonosensitizer according to claim 2, characterized in that: The operation process of (2) is as follows: under a nitrogen atmosphere, L-lysine-methylene blue-N-carboxyl ring anhydride, DMF and aminopolyethylene glycol monomethyl ether 5K are mixed, reacted at room temperature in the dark for 48 hours, the reaction solution is transferred to a dialysis bag with a molecular weight cutoff of 3500, dialyzed with water and then freeze-dried to obtain L-polylysine-methylene blue.
7. The method for preparing the sonosensitizer according to claim 2, characterized in that: The operation process of (3) is as follows: weigh 10 mg of L-polylysine-methylene blue, dissolve it in 2 mL of DMF, add it dropwise into 20 mL of deionized water while stirring, stir for 2-4 h to allow it to self-assemble into nanoparticles, then dialyze with deionized water for 24 h to remove DMF in the solution, and make the volume to 25 mL to obtain the sonosensitizer.
8. Use of the sonosensitizer according to claim 1 in sonodynamic therapy.
9. Use of the sonosensitizer according to claim 1 in preparing medicines.
10. An anti-tumor pharmaceutical composition, characterized in that: The method comprises the sonosensitizer according to claim 1 and an anticancer drug and / or an immune agonist loaded on the sonosensitizer.
Citation Information
Patent Citations
Amphipathic heparin-based block polymer and preparation method and application thereof
CN102977378A
Polyamino acid sound-sensitive agent and preparation method and application thereof
CN109395105A
Acoustic sensitive agent with low phototoxicity as well as preparation method and application of acoustic sensitive agent
CN114560885A
Application of NIR-activated methylene blue polyamino acid to co-delivery of cascade amplification photodynamic of nitric oxide
CN116966295A
A method of preparing pH / reduction responsive polyamino acid zwitterionic nanoparticles
US20200281865A1
Cited By
Nano sound-sensitive agent based on pMOF as well as preparation method and application of nano sound-sensitive agent
CN120550113A
